Bridge­Bio grabs a sec­ond pri­or­i­ty re­view for the port­fo­lio — giv­ing Per­cep­tive start­up cause to cel­e­brate

Just weeks af­ter get­ting its first NDA in — and grab­bing pri­or­i­ty re­view from the FDA in the process — Bridge­Bio says it’s lined up a sec­ond po­ten­tial speedy ap­proval for the port­fo­lio.

The hon­or goes to Bridge­Bio af­fil­i­ate QED Ther­a­peu­tics, which is de­vel­op­ing in­fi­gra­tinib as a cholan­gio­car­ci­no­ma treat­ment. In par­tic­u­lar, it had filed for ap­proval in sec­ond- and lat­er-line use.

It’s al­so good news for Lian­Bio, the Per­cep­tive start­up boast­ing a new mod­el for bring­ing West­ern drugs to Chi­na. In­fi­gra­tinib is one of the an­chor drugs of its in-li­censed port­fo­lio; in fact, Bridge­Bio CEO Neil Ku­mar has point­ed to the pro­gram as an ex­am­ple of Lian­Bio’s cre­ative strate­gies in tai­lor­ing de­vel­op­ment pro­grams for Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER